Pentamidine Isethionate

Class: Antiprotozoals, Miscellaneous
VA Class: AP100
Chemical Name: 4,4′-[1,5-Pentanediylbis(oxy)]bisbenzenecarboximidamide dimethanesulfonate
CAS Number: 140-64-7
Brands: NebuPent, Pentam 300

Introduction

Antiprotozoal; aromatic diamidine-derivative.1 2 3 4

Uses for Pentamidine Isethionate

Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia

Treatment of Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia (PCP); designated an orphan drug by FDA for this use.1 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 96 156 157 167 344

Parenteral pentamidine is an alternative to co-trimoxazole (the drug of choice) for treatment of pneumocystis pneumonia; can be used in patients who do not respond to or cannot tolerate co-trimoxazole,88 89 90 91 186 187 199 303 310 311 including those with a history of severe allergic reactions to either component of co-trimoxazole (i.e., sulfonamides or trimethoprim).88 186 199 310 311

Prevention of initial episodes of pneumocystis pneumonia (primary prophylaxis) in immunocompromised individuals at increased risk, including HIV-infected individuals; pentamidine oral inhalation designated an orphan drug by FDA for this use.79 216 219 220 221 230 231 278 285 295 342 343 347 356 357 Pentamidine given by oral inhalation is one of several alternatives that can be used in adults, adolescents, and children who cannot tolerate co-trimoxazole (the drug of choice).299 300 303 351 356 358

Slideshow: View Frightful (But Dead Serious) Drug Side Effects

Long-term suppressive or chronic maintenance therapy (secondary prophylaxis) to prevent recurrence following an initial episode of pneumocystis pneumonia in immunocompromised patients, including HIV-infected individuals; pentamidine oral inhalation designated an orphan drug by the FDA for this use.79 177 178 187 193 195 198 208 212 213 219 220 221 230 231 285 343 347 356 Pentamidine given by oral inhalation is one of several alternatives that can be used in adults, adolescents, and children who cannot tolerate co-trimoxazole (the drug of choice).299 300 303 351 356 358

African Trypanosomiasis

Treatment of trypanosomiasis caused by Trypanosoma brucei gambiense (Gambian sleeping sickness, West African trypanosomiasis).2 15 41 42 43 44 100 101 102 103 105 106 107 145 146 A drug of choice in early (hemolymphatic) stage of T. b. gambiense infection.41 43 44 91 105 303 Should not be used for late disease with CNS involvement since pentamidine penetrates the CNS poorly.15 43 44 100 101 102 103 105 146 303

Has been used with some success for treatment of trypanosomiasis caused by T. b. rhodesiense (Rhodesian sleeping sickness, East African trypanosomiasis).15 43 44 91 105 106 149 150 Other drugs preferred (e.g., suramin or melarsoprol [drugs not commercially available in US, but may be available from CDC]).91 303

Leishmaniasis

Has been effective for treatment of cutaneous and mucocutaneous leishmaniasis caused by various Leishmania spp.15 46 47 55 56 57 114 154 155 265 303 Usual drugs of choice are pentavalent antimony compounds (e.g., sodium stibogluconate or meglumine antimonate [drugs not commercially available in the US]);91 265 303 b pentamidine is an alternative and may be a drug of choice in patients who fail to respond to antimony compounds.91 303 b

Has been effective for treatment of visceral leishmaniasis (kala-azar) caused by Leishmania donovani.15 46 47 113 136 137 138 152 153 265 Usual drugs of choice for initial treatment of visceral leishmaniasis caused by L. donovani (usually endemic in Asia and Africa), L. infantum (usually endemic in the Mediterranean basin), or L. chagasi (usually endemic in Latin America) are pentavalent antimony compounds,46 113 265 but resistance and treatment failures are becoming increasingly common.265 Both IV amphotericin B and parenteral pentamidine are considered alternatives and have been effective in patients who failed to respond to antimony compounds.46 47 91 113 265 303

Pentamidine Isethionate Dosage and Administration

Administration

Administer by slow IV infusion or IM injection or by oral inhalation via nebulization.1 219

IV (not IM) route usually is recommended for treatment of pneumocystis pneumonia;91 199 oral inhalation is used for prophylaxis of pneumocystis pneumonia.91 356

Since severe hypotensive reactions can occur following IV or IM administration of pentamidine, patients should be in a supine position and BP should be monitored closely during and after parenteral administration of the drug.1 (See Hypotension and Other Cardiovascular Effects under Cautions.)

IV Administration

Avoid extravasation; irritating to tissues.1 Position the IV needle or catheter carefully; observe throughout the period of administration.1 If extravasation occurs, immediately stop the infusion and restart at another site.1 (See Local Effects under Cautions.)

Reconstitution and Dilution

Reconstitute vial containing 300 mg of pentamidine isethionate for injection with 3, 4, or 5 mL of sterile water for injection or 5% dextrose injection to provide a solution containing 100, 75, or 60 mg/mL, respectively.1

Dilute an appropriate volume of the reconstituted solution in 50–250 mL of 5% dextrose injection.1

Rate of Administration

IV infusions are given over 60–120 minutes to minimize the risk of hypotensive reactions.1 Do not administer by rapid IV injection or infusion.1 124

IM Administration

Administer by deep IM injection.1 Local adverse effects may be minimized by using the Z-tract technique (firmly push subcutaneous tissue aside before inserting the needle at a 90-degree angle).321

Reconstitution

Reconstitute vial containing 300 mg of pentamidine isethionate for injection with 3 mL of sterile water for injection to provide a solution containing 100 mg/mL.1

Oral Inhalation

Following reconstitution of the powder for oral inhalation (NebuPent), the solution is administered using a Respirgard II jet nebulizer.219 231 255

Consult the manufacturer's information for detailed administration instructions.219 231 255

Pentamidine isethionate for oral inhalation solution should not be admixed with any other drugs; the Respirgard II jet nebulizer should not be used to administer a bronchodilator.219

Reconstitution

Reconstitute vial containing 300 mg of pentamidine isethionate for oral inhalation (NebuPent) with 6 mL of sterile water for injection.219 Do not use sodium chloride solution; precipitation will occur.219

Rate of Administration

Place the reconstituted solution for oral inhalation into the reservoir of the Respirgard II jet nebulizer and deliver until the nebulizer chamber is empty (approximately 30–45 minutes) using a flow rate of 5–7 L/minute and an air or oxygen source at 40–50 PSI.219 231 Alternatively, use an air compressor delivering 40–50 PSI by setting the flowmeter at 5–7 L/minute or the pressure at 22–25 PSI; low-pressure (i.e., less than 20 PSI) air compressors should not be used.219 230

Dosage

Available as pentamidine isethionate in the US; dosage expressed as pentamidine isethionate.1 219

May be available outside the US as the mesylate salt; dosage of the mesylate salt is expressed as the base.160 206 Consider that dosages used in some published references may be unclear since the salt employed may not be specified.15 100 101 102 103 104 108 111 146 149 206 207

Pediatric Patients

Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia
Treatment
IV or IM

Children >4 months of age: 3–4 mg/kg once daily for 14–21 days.1 88 89 90 91 92 187 214 277 279

Adolescents: 3–4 mg/kg once daily for 14–21 days.91

Some patients may require more prolonged treatment;156 157 165 manufacturer cautions that therapy for >21 days may be associated with increased toxicity.1

Primary Prophylaxis
Inhalation

Children ≥5 years of age: 300 mg every 4 weeks (once monthly).91 219 230 299 300 310 312 319 351 356 The child must be capable of effectively using a nebulizer; other appropriate agents (co-trimoxazole, dapsone, atovaquone) recommended for younger children.356

In HIV-infected children 1–5 years of age, primary prophylaxis should be initiated if CD4+ T-cell counts are <500/mm3 or CD4+ percentage is <15%.356 358 In HIV-infected children 6–12 years of age, primary prophylaxis should be initiated if CD4+ T-cell counts are <200/mm3 or CD4+ percentage is <15%.356 358

Adolescents: Dosage and criteria for initiation or discontinuance of primary prophylaxis in this age group are the same as those recommended for adults.356 (See Adult Dosage under Dosage and Administration.)

Prevention of Recurrence (Secondary Prophylaxis)
Inhalation

Children ≥5 years of age: 300 mg every 4 weeks (once monthly).91 219 221 230 299 300 310 312 319 351 356 The child must be capable of effectively using a nebulizer; other appropriate agents (co-trimoxazole, dapsone, atovaquone) recommended for younger children.356

The safety of discontinuing secondary prophylaxis in HIV-infected children receiving potent antiretroviral therapy has not been extensively studied.365 Children who have a history pneumocystis pneumonia should receive life-long suppressive therapy to prevent recurrence.356

Adolescents: Dosage and criteria for initiation or discontinuance of secondary prophylaxis in this age group are the same as those recommended for adults.356 (See Adult Dosage under Dosage and Administration.)

African Trypanosomiasis
Treatment of Trypanosoma brucei gambiense Infections
IM

4 mg/kg once daily for 10 days recommended by CDC and others.91 143 214

Leishmaniasis
Treatment of Cutaneous Leishmaniasis
IV or IM

2–3 mg/kg once daily or every other day for 4–7 doses.91 265

Treatment of Visceral Leishmaniasis Caused by Leishmania donovani (Kala-azar)
IV or IM

2–4 mg/kg once daily or every other day for 15–30 doses recommended by CDC and others.91 143 214 Some clinicians recommend 4 mg 3 times weekly for 15–25 doses.265

Adults

Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia
Treatment
IV or IM

3–4 mg/kg once daily for 14–21 days.1 88 89 90 91 92 187 214 277 279

Some patients may require more prolonged treatment;156 157 165 manufacturer cautions that therapy for >21 days may be associated with increased toxicity.1

Primary Prophylaxis
Inhalation

300 mg every 4 weeks (once monthly).91 219 221 230 299 310 312 319 356

Initiate primary prophylaxis in patients with CD4+ T-cell counts <200/mm3 or a history of oropharyngeal candidiasis.356 Also consider primary prophylaxis if CD4+ T-cell percentage is <14% or there is a history of an AIDS-defining illness.356

Primary prophylaxis can be discontinued in adults and adolescents responding to potent antiretroviral therapy who have a sustained (≥3 months) increase in CD4+ T-cell counts from <200/mm3 to >200/mm3.356 However, it should be restarted if CD4+ T-cell count decreases to <200/mm3.356

Prevention of Recurrence (Secondary Prophylaxis)
Inhalation

300 mg every 4 weeks (once monthly).91 219 230 299 310 312 319 356

Initiate long-term suppressive therapy or chronic maintenance therapy (secondary prophylaxis) in those with a history of P. jiroveci pneumonia to prevent recurrence.356

Discontinuance of secondary prophylaxis is recommended in those who have a sustained (≥3 months) increase in CD4+ T-cell counts to >200/mm3 since such prophylaxis appears to add little benefit in terms of disease prevention and discontinuance reduces the medication burden, the potential for toxicity, drug interactions, selection of drug-resistant pathogens, and cost.356

Reinitiate secondary prophylaxis if CD4+ T-cell count decreases to <200/mm3 or if P. jiroveci pneumonia recurs at a CD4+ T-cell count >200/mm3.356 It probably is prudent to continue secondary prophylaxis for life in those who had P. jiroveci episodes when they had CD4+ T-cell counts >200/mm3.356

African Trypanosomiasis
Treatment of Trypanosoma brucei gambiense Infections
IM

4 mg/kg once daily for 10 days recommended by CDC and others.91 143 214

Leishmaniasis
Treatment of Cutaneous Leishmaniasis
IV or IM

2–3 mg/kg once daily or every other day for 4–7 doses.91 265

Treatment of Visceral Leishmaniasis Caused by Leishmania donovani (Kala-azar)
IV or IM

2–4 mg/kg once daily or every other day for 15–30 doses recommended by CDC and others.91 143 214 Some clinicians recommend 4 mg 3 times weekly for 15–25 doses.265

Special Populations

Renal Impairment

Some clinicians suggest that dosage adjustment may be needed if parenteral pentamidine is used in patients with severe renal impairment.77 131 132 133 185 Manufacturer states that parenteral pentamidine should be used with caution in patients with renal impairment and that safety and efficacy of alternative dosage regimens have not been established in these patients.1

Cautions for Pentamidine Isethionate

Contraindications

  • Known hypersensitivity to pentamidine or any ingredient in the formulation.1 219

Warnings/Precautions

Warnings

Hypotension and Other Cardiovascular Effects

Parenteral administration: Hypotension (which may develop suddenly and may be moderate to severe) may occur following IM or IV administration.1 15 41 43 52 83 86 87 124 159 167 188 202 279 Fatalities due to severe hypotension or cardiac arrhythmias reported.1 202 Hypotensive reactions most likely with rapid IV injection or infusion.1 15 21 124 159 188 202 279

When administering IV or IM pentamidine, place patient in a supine position.1 Monitor blood pressure during and after administration until blood pressure is stable; monitor ECGs.1

Appropriate equipment for maintenance of an adequate airway and other supportive measures and agents (e.g., IV fluids, vasopressor agents)124 159 for the management of hypotensive reactions should be readily available.1

Use with caution in patients with hypertension, hypotension, or ventricular tachycardia.1

Local Effects

IV administration: Extravasation may result in ulceration, tissue necrosis, and/or sloughing at the injection site; long-term sequelae reported.1 Manage symptomatically; surgical debridement and skin grafting may be needed.1

IM administration: Sterile abscess,1 81 83 86 124 pain,1 83 124 erythema,85 89 tenderness,85 89 and induration at injection site.1 85 89

Hypoglycemia and Diabetogenic Effects

Hypoglycemia1 31 32 33 34 35 81 83 84 85 86 87 88 89 90 95 165 167 169 180 188 202 243 (sometimes fatal) associated with pancreatic islet cell necrosis and high plasma insulin concentrations reported with IV or IM pentamidine.1

Hyperglycemia1 81 83 167 and insulin-dependent diabetes mellitus1 31 35 52 275 (which appears to be permanent in some cases)52 has occurred with or without preceding hypoglycemia1 275 and ketoacidosis1 in patients receiving parenteral therapy 31 52 or oral inhalation of the drug;275 these adverse effects sometimes occurred several months after discontinuance of parenteral therapy.1 31 52

Monitor blood glucose concentrations before, during (daily or every other day), and after therapy.1 135 169 165 180 329

Use with caution in patients with hypoglycemia or hyperglycemia.1

Pancreatitis

Acute pancreatitis1 128 166 168 322 335 (sometimes fatal)168 reported with IV or IM administration. Severe pancreatitis also reported rarely with orally inhaled pentamidine.219 246 274

Use parenteral pentamidine with caution in patients with pancreatitis.1 Discontinue orally inhaled pentamidine if acute pancreatitis occurs.219

Selection and Use for Treatment or Prevention of Pneumocystis Pneumonia

Use pentamidine for treatment of pneumocystis pneumonia only in patients in whom the presence of P. jiroveci has been demonstrated.1

Dosage of orally inhaled pentamidine used for prophylaxis is insufficient for treatment of acute pneumocystis pneumonia.219 Prior to initiating primary prophylaxis, evaluate symptomatic patients to rule out P. jiroveci infection.219

Consider that orally inhaled pentamidine may not be completely protective and some patients receiving the drug for prophylaxis may develop acute pneumocystis pneumonia.219 230 278 Extrapulmonary and/or disseminated infection also reported occasionally during prophylaxis,200 219 231 236 239 240 249 276 278 usually in patients with a history of pneumocystis pneumonia.219 236 240 249 276

Monitor patients for signs and symptoms of pulmonary infection (e.g., fever, cough, dyspnea) prior to and during prophylaxis; evaluate those with signs or symptoms to rule out infection caused by P. jiroveci or other opportunistic or nonopportunistic pathogens.219 223 239 247 249 If pneumocystis pneumonia develops, discontinue prophylaxis and institute treatment with co-trimoxazole, parenteral pentamidine, or another effective regimen.195 221 223 247 248 Prophylaxis can be reinstituted when treatment is complete.221 247

Respiratory Effects

Cough and bronchospasm reported frequently with orally inhaled pentamidine,219 231 277 278 279 especially in those with a history of smoking or asthma.174 208 211 212 217 Bronchospasm also reported after parenteral administration.1 210

Cough or bronchospasm in patients receiving pentamidine by oral inhalation can be controlled in most patients by interrupting pentamidine treatment and administering a bronchodilator.193 211 212 219 278 279 Coughing also may be controlled by slowing the delivery or intensity of the pentamidine aerosol stream.193 195 211 212 217

Pretreatment with an orally inhaled bronchodilator may minimize the occurrence of coughing and bronchospasm.176 177 178 193 208 211 212 279 315 316

Sensitivity Reactions

Parenteral administration: Allergic reactions reported, including pruritus,83 101 210 local or generalized urticaria,52 124 167 210 rash1 83 95 124 167 279 337 (e.g., maculopapular, pruritic),124 337 anaphylaxis,1 Stevens-Johnson syndrome,1 83 and toxic epidermal necrolysis.125 Use with caution in patients with Stevens-Johnson syndrome.1 219

Oral inhalation: Allergic reactions reported.219

Major Toxicities

Renal Effects

Parenteral administration: Nephrotoxicity (increase in Scr and/or BUN, azotemia, renal insufficiency, renal failure) reported.1 52 83 84 85 86 87 89 90 95 96 167 169 188 202 271 279

Monitor renal function (BUN, Scr) before, during (daily or every other day), and after therapy.1 135 165 169 329 Consider monitoring serum potassium concentrations, particularly in AIDS patients.258 259 Ensure that patients are well hydrated; monitor fluid status.258 259 (See Renal Impairment under Cautions.)

Hepatic Effects

Parenteral administration: Elevated liver function test results reported.1 83 87 95 167 169 174 202 Monitor hepatic function (serum bilirubin, alkaline phosphatase, AST, ALT) before, during, and after therapy.1 (See Hepatic Impairment under Cautions.)

Hematologic Effects

Parenteral administration: Leukopenia (e.g., neutropenia)1 95 188 202 279 and thrombocytopenia,1 83 95 167 188 202 279 which can be severe (e.g., leukocyte count <1000/mm3, platelet count <20,000/mm3),1 95 occur occasionally in patients receiving parenteral pentamidine.1 83 95 188 202 Anemia occurs rarely.1 83 167

Oral inhalation: Neutropenia has occurred in several patients receiving the drug by oral inhalation,174 219 but these patients generally had low pretreatment leukocyte counts associated with zidovudine therapy.174

Monitor CBCs and platelet counts.1 Use with caution in patients with leukopenia, thrombocytopenia, or anemia.1 219

General Precautions

Consider that serious adverse effects reported with parenteral pentamidine also may occur with oral inhaled pentamidine.174 203 219

Laboratory Monitoring

Monitor renal function (BUN, Scr) before, during (daily or every other day), and after parenteral therapy.1 135 165 169 329 Consider monitoring serum potassium concentrations, particularly in AIDS patients.258 259 Also monitor renal function and for hyperkalemia in patients receiving orally inhaled pentamidine.219

Monitor hepatic function (serum bilirubin, alkaline phosphatase, AST, ALT) before, during, and after parenteral therapy.1 Also monitor hepatic function in patients receiving orally inhaled pentamidine.219 (See Hepatic Impairment under Cautions.)

Monitor blood glucose concentrations before, during (daily or every other day), and after parenteral therapy.1 135 169 165 180 329 Also monitor for hypoglycemia and hyperglycemia in patients receiving orally inhaled pentamidine.219

Because hypocalcemia has been reported with parenteral pentamidine, monitor serum calcium concentrations before, during, and after therapy.1 83 167 Also monitor for hypocalcemia in patients receiving orally inhaled pentamidine.219

Environmental Exposure of Health-care Personnel and Visitors

The potential risks of environmental exposure to aerosolized pentamidine by health-care personnel and visitors in contact with patients receiving pentamidine inhalation therapy are unknown.205 211 212 230 247 251 252 261 264 285 Adverse effects have been reported in health-care personnel and others exposed to aerosolized pentamidine (e.g., perioral and perinasal paresthesia;263 burning sensation of the eyes, nose, and throat;264 sinus irritation;264 shortness of breath;262 264 338 cough;264 tightness of the chest;264 338 acute bronchospasm;262 headache;264 light-headedness).264

CDC and others recommend that health-care personnel administering aerosolized pentamidine be familiar with the manufacturer's instructions for use of the nebulizer delivery system, since improper use of the nebulizer potentially could result in release of substantial amounts of pentamidine into the environment.230 247 261 Some clinicians suggest that pregnant women205 261 264 and possibly those planning to become pregnant (e.g., within 8 weeks of potential exposure)264 avoid environmental exposure to aerosolized pentamidine. Consult specialized sources for recommended procedures to minimize environmental exposure to drug.211 212 251 261 262 264

Because cough and bronchospasm frequently occur in patients receiving orally inhaled pentamidine,219 231 277 278 279 health-care personnel who administer pentamidine inhalation therapy may be at risk of exposure to tuberculosis if the patient has undiagnosed Mycobacterium tuberculosis infection.230 250 264 266 285 310 311

Specific Populations

Pregnancy

Category C.1 219

Lactation

Not known whether pentamidine distributed into milk.134 219 Discontinue nursing or the drug.1 219

Pediatric Use

Parenteral administration: Safety and efficacy established in children >4 months of age.1 Has been used effectively for treatment of pneumocystis pneumonia in younger children1 81 83 85 86 87 89 90 130 (including neonates);1 83 85 86 90 130 no unusual risks associated with the drug identified.85 89 90 130 134 Also has been used effectively and apparently without unusual risks for treatment of African trypanosomiasis91 100 101 and leishmaniasis53 91 in children.

Oral inhalation: Safety and efficacy not established in children ≤16 years of age.219 AAP, USPHS/IDSA, and others state that use of orally inhaled pentamidine can be considered in children ≥5 years of age who are capable of effectively using a nebulizer.299 300 303 356

Hepatic Impairment

Caution in patients with hepatic impairment.1 219 Safety and efficacy of alternative parenteral dosage regimens in these patients not established.1

Renal Impairment

Caution in patients with renal impairment.1 Safety and efficacy of alternative dosage regimens in these patients not established.1

Common Adverse Effects

Parenteral administration: Nephrotoxicity;1 83 84 85 86 87 89 96 167 169 188 202 271 hypotension;1 15 41 43 52 83 86 87 124 159 167 188 202 279 hepatic effects;1 83 87 95 167 169 174 202 GI effects (anorexia, nausea, vomiting);1 52 83 90 167 202 219 278 279 hematologic effects (leukopenia);1 95 188 202 279 hypoglycemia;1 31 32 33 34 35 81 83 84 85 86 87 88 89 90 95 165 167 169 180 188 202 243 injection site reactions.1 81 83 86 124

Oral inhalation: Respiratory effects (cough, bronchospasm, wheezing, shortness of breath);219 220 222 230 231 278 279 GI effects (diarrhea, nausea, decreased appetite).219

Interactions for Pentamidine Isethionate

Nephrotoxic Drugs

Nephrotoxic effects may be additive; the concurrent or sequential use of other drugs with similar toxic potentials (e.g., aminoglycosides, amphotericin B, capreomycin, colistin, cisplatin, foscarnet, methoxyflurane, polymyxin B, vancomycin) should be closely monitored or avoided, if possible.1 83 84 85 87 219

Pentamidine Isethionate Pharmacokinetics

Absorption

Bioavailability

Well absorbed following IM administration.1 77

Bronchoalveolar lavage fluid concentrations attained following oral inhalation are substantially higher (at least 5–10 times) than those attained following IV administration.174 181 182 211 212 213 219 277

Pentamidine appears to undergo limited absorption from the respiratory tract into systemic circulation.174 181 182

Plasma Concentrations

Peak plasma concentrations following oral inhalation are ≤5% of those attained following IV administration.182

Special Populations

Plasma pentamidine concentrations following parenteral administration are higher in patients with renal impairment.1 77

Distribution

Extent

Rapidly and extensively distributed and/or bound to tissues.77 171 183 Following parenteral administration, highest concentrations are found in the liver, followed by the kidneys, adrenals, spleen, lungs, and pancreas in AIDS patients.183

Penetrates the CNS poorly.2 15 43 44 100 101 102 103 105 111

Deposition of orally inhaled pentamidine shows considerable interindividual variation; appears to depend on several factors, including delivery device, particle size of aerosolized drug, dose, patient position, and nebulization efficiency.181 182 219 284 293 296

Crosses the placenta;355 not known whether the drug is distributed into milk.134

Plasma Protein Binding

69%.172

Elimination

Elimination Route

Excreted in urine as unchanged drug;77 171 185 renal clearance accounts for ≤5% of total body clearance.171 172 185

Not appreciably removed by hemodialysis or peritoneal dialysis.185

Half-life

IV administration: 6.4 hours.1 171

IM administration: 9.4 hours.1 171

Eliminated very slowly from tissues where the drug accumulates (e.g., liver, lungs).182 183

Special Populations

Parenteral administration: Half-life not substantially altered in patients with mild to moderate renal impairment, but half-life may be prolonged up to ≥2 days in those with severe renal impairment.185

Oral inhalation: Information not available on pharmacokinetics of the drug in patients with renal or hepatic impairment.219

Stability

Storage

Parenteral

Powder for Injection

15–30°C; protect from light.1

Following reconstitution with sterile water for injection, stable for 48 hours in the original vial if protected from light.1 Store at 22–30°C to avoid crystallization.1

Following dilution with 5% dextrose in water to a concentration of 1 mg/mL or 2.5 mg/mL, stable at room temperature for up to 24 hours.1

Oral Inhalation

Powder for Inhalation Solution

15–30°C; protect from light.219 Following reconstitution with sterile water for injection, stable for 48 hours in the original vial if protected from light.219

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution CompatibilityHID

Compatible

Dextrose 5% in water

Sodium chloride 0.9%

Drug Compatibility
Y-site CompatibilityHID1

Compatible

Diltiazem HCl

Zidovudine

Incompatible

Aldesleukin

Cefazolin sodium

Cefotaxime sodium

Cefoxitin sodium

Ceftazidime

Ceftriaxone sodium

Fluconazole

Foscarnet sodium

Lansoprazole

Linezolid

Oral Inhalation

Do not mix with other drugs.219

Actions and Spectrum

Advice to Patients

  • Importance of completing full course of therapy.219

  • When used for the prevention of pneumocystis pneumonia, importance of informing clinicians if symptoms of a pulmonary infection (cough, fever, dyspnea) occur.219

  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1 219

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 219

  • Importance of informing patients of other important precautionary information.1 219 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Pentamidine Isethionate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral Inhalation

For inhalation solution

300 mg

NebuPent

Abraxis

Parenteral

For injection

300 mg*

Pentam 300

Abraxis

Pentamidine Isethionate for Injection

Baxter, Hospira, Steris

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 3, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. American Pharmaceutical Partners. Pentam 300 (pentamidine isethionate) for injection prescribing information. Los Angeles, CA; 1999 Apr.

2. Schoenbach EB, Greenspan EM. The pharmacology, mode of action and therapeutic potentialities of stilbamidine, pentamidine, propamidine and other aromatic diamidines—a review. Medicine (Baltimore). 1948; 27:327-77. [PubMed 18885033]

3. Wien R. The pharmacological actions of certain aromatic diamidines possessing trypanocidal activity. Ann Trop Med Parasit. 1943; 37:1-18.

4. Lourie EM, Yorke W. Studies in chemotherapy. XXI. The trypanocidal action of certain aromatic diamidines. Ann Trop Med Parasit. 1939; 33:289-304.

5. Ashley JN, Barber HJ, Ewins AJ et al. A chemotherapeutic comparison of the trypanocidal action of some aromatic diamidines. J Chem Soc. 1942; 20:103-16.

6. The British pharmacopoeia. London: Her Majesty's Stationery Office; 1980:330.

7. Windholz M, ed. The Merck index. 10th ed. Rahway, NJ: Merck & Co, Inc; 1983:1023.

8. Chesters JK. Protein synthesis by cell-free extracts of Crithidia oncopelti. Biochim Biophys Acta. 1966; 114:385-97.

9. Wallis DC. The effect of pentamidine on ribosomes of the parasitic flagellate Crithidia (Strigomonas) oncopelti. J Protozool. 1966; 13:234-9.

10. Bachrach U, Brem S, Wertman SB et al. Leishmania spp.: effect of inhibitors on growth and on polyamine and macromolecular syntheses. Exp Parasitol. 1979; 48:464-70. [PubMed 510448]

11. Gutteridge WE. Some effects of pentamidine di-isethionate on Crithidia fasciculata. J Protozool. 1969; 16:306-11.

12. Kaplan HG, Myers CE. Complex inhibition of thymidylate synthetase by aromatic diamidines: evidence for both rapid, freely reversible and slowly progressive, nonequilibrium inhibition. J Pharmacol Exp Ther. 1977; 201:554-63. [PubMed 864595]

13. Hill GC, Hutner SH. Effect of trypanocidal drugs on terminal respiration of Crithidia fasciculata. Exp Parasitol. 1968; 22:207-12.

14. Bornstein RS, Yarbro JW. An evaluation of the mechanism of action of pentamidine isethionate. J Surg Oncol. 1970; 2:393-8. [PubMed 5315524]

15. Rollo IM. Miscellaneous drugs used in the treatment of protozoal infections. In: Gilman AG, Goodman L, Goodman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Company; 1980:1071-2.

16. Bowman WC, Rand MJ, eds. Chapter 36: Chemotherapy of protozoal infections. In: Textbook of pharmacology. 2nd ed. Oxford: Blackwell Scientific Publications; 1980.

17. Makulu DR, Waalkes TP. Interaction between aromatic diamidines and nucleic acids: possible implications for chemotherapy. J Natl Cancer Inst. 1975; 54:305-9. [PubMed 234535]

18. Festy B, Sturm J, Daune M. Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975; 407:24-42. [PubMed 1242363]

19. Williamson J. Effects of trypanocides on the fine structure of target organisms. Pharmacol Ther. 1979; 7:445-512. [PubMed 392561]

20. Macadam RF, Williamson J. Drug effects on the fine structure of Trypanosoma rhodesiense: diamidines. Trans R Soc Trop Med Hyg. 1972; 66:897-904. [PubMed 4678907]

21. Hentzer B, Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Parasitol. 1977; 71:157-66. [PubMed 869606]

22. Croft SL, Brazil RP. Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann Trop Med Parasitol. 1982; 76:37-43. [PubMed 7082077]

23. Langreth SG, Berman JD, Riordan GP et al. Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro. J Protozool. 1983; 30:555-61. [PubMed 6315928]

24. Waalkes TP, Makulu DR. Pharmacologic aspects of pentamidine. Natl Cancer Inst Monogr. 1976; 43:171-6. [PubMed 1018718]

25. Jaffe JJ, McCormack JJ Jr, Gutteridge WE. Dihydrofolate reductases within the genus Trypanosoma. Exp Parasitol. 1969; 25:311-8.

26. Robbins JB, Miller RH, Arean VM et al. Successful treatment of Pneumocystis carinii pneumonitis in a patient with congenital hypogammaglobulinemia. N Engl J Med. 1965; 272:708-13. [PubMed 14261461]

27. Steck EA, Kinnamon KE. Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types. Exp Parasitol. 1981; 52:404-13. [PubMed 7032963]

28. Pesanti EL. In vitro effects of antiprotozoan drugs and immune serum on Pneumocystis carinii. J Infect Dis. 1980; 141:775-80.

29. Pesanti EL, Cox C. Metabolic and synthetic activities of Pneumocystis carinii in vitro. Infect Immun. 1981; 34:908-14. [PubMed 6174453]

30. Pifer LL, Pifer DD, Woods DR. Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture. Antimicrob Agents Chemother. 1983; 24:674-8. [PubMed 6607029]

31. Bouchard P, Sai P, Reach G et al. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes. 1982; 31:40-5. [IDIS 145888] [PubMed 6759211]

32. Klinkhamer LV. Hypoglycaemia during pentamidine treatment for trypanosomiasis. Trop Geogr Med. 1958; 10:332-6. [PubMed 13635851]

33. Fitzgerald DB, Young IS. Reversal of pentamidine-induced hypoglycaemia with oral diazoxide. J Trop Med Hyg. 1984; 87:15-9. [IDIS 191888] [PubMed 6371261]

34. Raia JJ, Patton LR, Klein RA et al. Prolonged hypoglycemia during pentamidine therapy. Clin Pharm. 1983; 2:505-6. [IDIS 178532] [PubMed 6653049]

35. Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg. 1984; 78:252-3. [IDIS 191886] [PubMed 6464116]

36. Sai P, Boillot D, Boitard C et al. Pentamidine, a new diabetogenic drug in laboratory rodents. Diabetologia. 1983; 25:418-23. [PubMed 6360780]

37. Osei K, Falko JM, Nelson KP et al. Diabetogenic effect of pentamidine: in vitro and in vivo studies in a patient with malignant insulinoma. Am J Med. 1984; 77:41-6. [IDIS 187519] [PubMed 6331162]

38. Bielenberg VGW, Krieglstein J. Uber die blutdrucksenkende Wirkung aromatischer Amidine und Imidazoline. (German; with English abstract) Arzneim-Forsch. 1984; 34:958-67.

39. Macintosh FC, Paton WDM. The liberation of histamine by certain organic bases. J Physiol. 1949; 109:190-219. [PubMed 15394320]

40. Kempin SJ, Jackson CW, Edwards CC. In vitro inhibition of platelet function and coagulation by pentamidine isethionate. Antimicrob Agents Chemother. 1977; 12:451-4. [IDIS 93656] [PubMed 921238]

41. Spencer HC. African trypanosomiasis. In: Strickland GT, ed. Hunter's tropical medicine. 6th ed. Philadelphia: WB Saunders; 1984: 553-64.

42. Eyckmans L. Trypanosoma species (African sleeping sickness). In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley & Sons; 1985:1537-40.

43. Apted FIC. Treatment of human trypanosomiasis. In: Mulligan H, Potts WH, eds. The African trypanosomiases. London: George Allen & Unwin; 1970:684-710.

44. Report of a Joint WHO Expert Committee and FAO Expert Consultation. The African trypanosomiases. Technical Report Series No. 635. Geneva: World Health Organization; 1979.

45. Kirchhoff LV, Neva FA. Trypanosoma species (Chagas' disease). In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley & Sons; 1985:1531-7.

46. Report of a WHO Expert Committee. The Leishmaniases. Technical Report Series No. 701. Geneva: World Health Organization; 1984.

47. Pearson RD, De Queiroz Sousa A. Leishmania species (kala-azar, cutaneous and mucocutaneous leishmaniasis). In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley & Sons; 1985:1522-31.

48. Collier HOJ, Lourie EM. The action in vitro of diamidines and other compounds on Leishmania donovani. Ann Trop Med Parasitol. 1946; 40:88-100.

49. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis. 1980; 142:83-6. [PubMed 6249874]

50. Berman JD. In vitro susceptibility of antimony-resistant Leishmania to alternative drugs. J Infect Dis. 1982; 145:279. [IDIS 146093] [PubMed 6274970]

51. Berman JD, Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol. 1984; 70:220-5. [PubMed 6088749]

52. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg. 1983; 77:167-70. [IDIS 191889] [PubMed 6868096]

53. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg. 1984; 78:391-8. [IDIS 191887] [PubMed 6087515]

54. Thakur CP, Kumar M, Singh SK et al. Comparisons of regimens of treatment with sodium stibogluconate in kala-azar. BMJ. 1984; 288:895-7. [IDIS 184013] [PubMed 6322906]

55. Zaar K, Wunderlich F. Electron microscopical studies on cutaneous leishmaniasis in Ethiopia. I. The diffuse form and its treatment with pentamidine. Ann Trop Med Parasitol. 1982; 76:595-605. [IDIS 191902] [PubMed 7171248]

56. Bryceson ADM. Diffuse cutaneous leishmaniasis in Ethiopia. II. Treatment. Trans R Soc Trop Med Hyg. 1970; 64:369-79. [PubMed 5453496]

57. Low-a-chee RM, Rose P, Ridley DS. An outbreak of cutaneous leishmaniasis in Guyana: epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol. 1983; 77:255-60. [PubMed 6625725]

58. Chulay JD. Cutaneous leishmaniasis of the new world. In: Strickland GT, ed. Hunter's tropical medicine. 6th ed. Philadelphia: WB Saunders; 1984:589-93.

59. Lourie EM, Yorke W. Studies in chemotherapy. XXI. The trypanocidal action of certain aromatic diamidines. Ann Trop Med Hyg. 1939; 33:289-304.

60. Adler S, Tchernomoretz I, Ber M. The action of some aromatic diamidines on cultures of Leishmania donovani. Ann Trop Med Parasitol. 1945; 39:14-9.

61. Lourie EM, Yorke W. Studies in chemotherapy. XXII. The action of certain aromatic diamidines on Babesia canis infections of puppies. Ann Trop Med Parasitol. 1939; 33:305-12.

62. Miller LH, Neva FA, Gill F. Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters. Ann Intern Med. 1978; 88:200-2. [IDIS 77374] [PubMed 626449]

63. Ruebush TK II, Contacos PG, Steck EA. Chemotherapy of Babesia microti infections in Mongolian jirds. Antimicrob Agents Chemother. 1980; 18:289-91. [PubMed 7447406]

64. Stenderup A. Effect of diamidines on Candida albicans in vitro. Acta Pathol Microbiol Scand. 1955; 36:361-4. [PubMed 14387697]

65. Fahlberg WJ. A comparison of fungistatic properties of three aromatic diamidines. Proc Soc Exp Biol Med. 1953; 84:84-7. [PubMed 13120942]

66. Stenderup A, Bichel J, Kissmeyer-Nielsen F. Moniliasis treated with pentamidine. Lancet. 1956; 1:20-1.

67. Bocobo FC, Curtis AC, Harrell ER. In vitro fungistatic activity of stilbamidine, propamidine, pentamidine and diethylstilbestrol. J Invest Dermatol. 1953; 21:149-56. [PubMed 13084980]

68. Christison IB, Conant NF. Antifungal activity of some aromatic diamidines. J Lab Clin Med. 1953; 42:638-40. [PubMed 13096901]

69. Bichowsky-Slomnitzki L. The effect of aromatic diamidines on bacterial growth. I. The mechanism of action. J Bacteriol. 1948; 55:27-31.

70. Amos H, Vollmayer E. Effect of pentamidine on the growth of Escherichia coli. J Bacteriol. 1957; 73:172-7.

71. Eaton MD, Perry ME, Levenson CG et al. Studies on the mode of action of aromatic diamidines on influenza and mumps virus in tissue culture. J Immunol. 1952; 68:321-34. [PubMed 14938548]

72. Williamson J. Review of chemotherapeutic and chemoprophylactic agents. In: Mulligan H, Potts WH, eds. The African trypanosomiases. London: George Allen & Unwin; 1970:125-221.

73. Williamson J. Drug resistance in trypanosomes: effects of metabolic inhibitors, pH and oxidation-reduction potential on normal and resistant Trypanosoma rhodesiense. Bur J Pharmacol. 1959; 14:443-55.

74. Damper D, Patton CL. Pentamidine transport and sensitivity in brucei-group trypanosomes. J Protozool. 1976; 23:349-56. [PubMed 6797]

75. Damper D, Patton CL. Pentamidine transport in Trypanosoma brucei—kinetics and specificity. Biochem Pharmacol. 1976; 25:271-6. [PubMed 1267824]

76. Wallis OC. Pentamidine resistance in the parasitic flagellate Crithidia (Strigomonas) oncopelti. J Protozool. 1966; 13:230-4.

77. Waalkes TP, Denham C, DeVita VT. Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther. 1970; 11:505-12. [IDIS 15141] [PubMed 5310706]

78. Waldman RH, Pearce DE, Martin RA. Pentamidine isethionate levels in lungs, livers, and kidneys of rats after aerosol or intramuscular administration. Am Rev Respir Dis. 1973; 108:1004-6. [PubMed 4355009]

79. Food and Drug Administration. Cumulative list of orphan drug and biologic designations. [Docket No. 84N-0102] Fed Regist. 1988; 53:2680-8.

80. Robbins JB. Pneumocystis carinii pneumonitis: a review. Pediatr Res. 1967; 1:131-58. [PubMed 5339830]

81. Burke BA, Good RA. Pneumocystis carinii infection. Medicine (Baltimore). 1973; 52:23-51. [PubMed 4540153]

82. Goodell B, Jacobs JB, Powell RD et al. Pneumocystis carinii: the spectrum of diffuse interstitial pneumonia in patients with neoplastic diseases. Ann Intern Med. 1970; 72:337-40. [PubMed 5308994]

83. Western KA, Perera DR, Schultz MG. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1970; 73:695-702. [IDIS 17454] [PubMed 5312203]

84. Walzer PD, Perl DP, Krogstad DJ et al. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974; 80:83-93. [IDIS 191892] [PubMed 4589515]

85. Hughes WT, Price RA, Kim HK et al. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr. 1973; 82:404-15. [PubMed 4572932]

86. Lipson A, Marshall WC, Hayward AR. Treatment of Pneumocystis carinii pneumonia in children. Arch Dis Child. 1977; 52:314-9. [IDIS 85385] [PubMed 301010]

87. Geelhoed GW, Hubbard SB, Powell RD et al. Clinical characteristics of Pneumocystis carinii pneumonia. Am Surg. 1979; 45:293-304. [PubMed 313176]

88. Winston DJ. Pneumocystis carinii pneumonia. Compr Ther. 1981; 7(6):41-8. [IDIS 191896] [PubMed 6972850]

89. Hughes WT, Feldman S, Chaudhary SC et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1978; 92:285-91. [IDIS 102397] [PubMed 304478]

90. Siegel SE, Wolff LJ, Baehner RL et al. Treatment of Pneumocystis carinii pneumonitis. A comparative trial of sulfamethoxazole-trimethoprim v pentamidine in pediatric patients with cancer: report from the Children's Cancer Study Group. Am J Dis Child. 1984; 138:1051-4. [IDIS 192144] [PubMed 6388315]

91. Anon. Drugs for parasitic infections. Med Lett Drugs Ther. Aug 2004. From the Medical Letter website.

92. Murray JF, Felton CP, Garay SM et al. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute Workshop. N Engl J Med. 1984; 310:1682-8. [PubMed 6328301]

93. Haverkos HW. Assessment of therapy for Pneumocystis carinii pneumonia. PCP Therapy Project Group. Am J Med. 1984; 76:501-8. [IDIS 183728] [PubMed 6367458]

94. Jaffe HS, Abrams DI, Ammann AJ et al. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983; 2:1109-11. [IDIS 178234] [PubMed 6138645]

95. Gordin FM, Simon GL, Wofsy CB et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 100:495-9. [IDIS 183827] [PubMed 6230976]

96. Kovacs JA, Hiemenz JW, Macher AM et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984; 100:663-71. [PubMed 6231873]

97. Kochen MM, Herrmann C, Goebel FD. Pentamidine of co-trimoxazole for Pneumocystis carinii pneumonia. Lancet. 1983; 2:1300-1. [IDIS 178673] [PubMed 6139634]

98. Gibbons RB, Lindauer JA. Successful treatment of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in hypersensitive AIDS patients. JAMA. 1985; 253:1259-60. [IDIS 196293] [PubMed 3871490]

99. Kluge RM, Spaulding DM, Spain AJ. Combination of pentamidine and trimethoprim-sulfamethoxazole in the therapy of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother. 1978; 13:975-8. [PubMed 307941]

100. Lawson TL. Trypanosomiasis treated with ″pentamidine'. Lancet. 1942; 2:480-3.

101. Lourie EM. Treatment of sleeping sickness in Sierra Leone. Ann Trop Med Parasitol. 1942; 36:113-31.

102. Harding RD. Trypanosomiasis treated with pentamidine. Br Med J. 1944; 2:447.

103. Van Hoof L, Henrard C, Peel E. Pentamidine in the prevention and treatment of trypanosomiasis. Trans R Soc Trop Med Hyg. 1944; 37:271-80.

104. Van Hoof L, Lewillon R, Henrard C et al. A field experiment on the prophylactic value of pentamidine in sleeping sickness. Trans Roy Soc Trop Med Hyg. 1946: 39:327-9.

105. Manson's tropical diseases. 18th ed. Manson-Bahr PEC, Apted FIC, eds. London: Baillière Tindall; 1982:80-3.

106. Apted FIC. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Eastern hemisphere. Pharmacol Ther. 1980; 11:391-413. [PubMed 7001502]

107. Molyneux DH. Selective primary health care: strategies for control of disease in the developing world. VIII. African trypanosomiasis. Rev Infect Dis. 1983; 5:945-56. [IDIS 176530] [PubMed 6635428]

108. Gall D. The chemoprophylaxis of sleeping sickness with the diamidines. Ann Trop Med Parasitol. 1954; 48:242-58. [PubMed 13208153]

109. Waddy BB. Chemoprophylaxis of human trypanosomiasis. In: Mulligan H, Potts WH, eds. The African trypanosomiases. London: George Allen & Unwin; 1970:711-25.

110. Barrett-Connor E. Chemoprophylaxis of amebiasis and African trypanosomiasis. Ann Intern Med. 1972; 77:797-805. [PubMed 4263577]

111. Marr JJ. Antiparasitic agents. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley & Sons; 1985:286-301.

112. Greenwood BM. African trypanosomiasis (sleeping sickness). In: Wyngaarden JB, Smith LH Jr, eds. Cecil textbook of medicine. 16th ed. Philadelphia: WB Saunders Company; 1982: 1725-8.

113. Chulay JD, Manson-Bahr PEC. Visceral leishmaniasis (kala-azar). In: Strickland GT, ed. Hunter's tropical medicine. 6th ed. Philadelphia: WB Sauders Company; 1984:578-85.

114. Chulay JD, Manson-Bahr PEC. Cutaneous leishmaniasis of the old world. In: Strickland GT, ed. Hunter's tropical medicine. 6th ed. Philadelphia: WB Sauders Company; 1984:585-9.

115. Francioloi PB, Keithly JS, Jones TC et al. Response of babesiosis to pentamidine therapy. Ann Intern Med. 1981; 94:326-30. [IDIS 128945] [PubMed 7194615]

116. Ortiz JM, Eagle RC Jr. Ocular findings in human babesiosis (Nantucket fever). Am J Ophthalmol. 1982; 93:307-11. [IDIS 146816] [PubMed 7200325]

117. Jacoby GA, Hunt JV, Kosinski KS et al. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med. 1980; 303:1098-1100. [IDIS 123360] [PubMed 7191475]

118. Teutsch SM, Etkind P, Burwell EL et al. Babesiosis in post-splenectomy hosts. Am J Trop Med Hyg. 1980; 29:738-41. [IDIS 191904] [PubMed 7192058]

119. Gombert ME, Goldstein EJC, Benach JL et al. Human babesiosis: clinical and therapeutic considerations. JAMA. 1982; 248:3005-7. [IDIS 161440] [PubMed 6890585]

120. Teutsch SM, Juranek DD. Babesiosis. Ann Intern Med. 1981; 95:241.

121. Ruebush TK II, Spielman A. Human babesiosis in the United States. Ann Intern Med. 1978; 88:263. [IDIS 77989] [PubMed 564654]

122. Ruebush TK II. Babesia. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley & Sons; 1985:1559-60.

123. DeVita VT, Emmer M, Levine A et al. Pneumocystis carinii pneumonia. Successful diagnosis and treatment of two patients with associated malignant processes. N Engl J Med. 1969; 280:287-91. [PubMed 5303991]

124. Navin TR, Fontaine RE. Intravenous versus intramuscular administration of pentamidine. N Engl J Med. 1984; 311:1701-2. [IDIS 194109] [PubMed 6504113]

125. Wang JJ, Freeman AI, Gaeta JF et al. Unusual complications of pentamidine in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1970; 77:311-4. [IDIS 13410] [PubMed 5310885]

126. Anon. Severe neutropenia during pentamidine treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome—New York City. MMWR Morb Mortal Wkly Rep. 1984; 33:65-7. [PubMed 6422241]

127. Levy MA, Senior RM, Sneider RE. Severe thrombocytopenic purpura complicating pentamidine therapy for Pneumocystis carinii pneumonia. Cancer. 1974; 34:441-3. [IDIS 44565] [PubMed 4546914]

128. Murphey SA, Josephs AS. Acute pancreatitis associated with pentamidine therapy. Arch Intern Med. 1981; 141:56-8. [IDIS 129855] [PubMed 6969581]

129. Stark FR, Crast F, Clemmer T et al. Fatal Herxheimer reaction after pentamidine in pneumocystis pneumonia. Lancet. 1976; 1:1193-4. [IDIS 61703] [PubMed 58250]

130. Ivady G, Paldy L. Treatment of Pneumocystis carinii pneumonia in infancy. Natl Cancer Inst Monogr. 1976; 43:201-8. [IDIS 191895] [PubMed 1087956]

131. Bennett WM, Muther RS, Parker RA et al. Drug therapy in renal failure: dosing guidelines for adults. Part I. Antimicrobial agents, analgesics. Ann Intern Med. 1980; 93(Part 1):62-89. [IDIS 122057] [PubMed 6994534]

132. Kuller J, First MR, D'Achiardi R et al. Pneumocystis carinii pneumonia in renal transplant recipients. Am J Nephrol. 1982; 2:312-5. [IDIS 191900] [PubMed 6762092]

133. Chatterjee SN, Gottlieb L, Berne TV. Fulminant pulmonary infections in renal transplant recipients. Surg Gynecol Oncol. 1978; 147:583-7.

134. Komos DM (LyphoMed, Inc, Melrose Park, IL): Personal communication; 1985 Apr.

135. Reviewers' comments (personal observations).

136. Hazarika AN. Treatment of kala-azar with pentamidine isothionate: a study of 55 cases. Indian Med Gaz. 1949; 84:140-5.

137. Sen Gupta PC. The treatment of kala-azar and its complications. J Indian Med Assoc. 1949; 18:377-82.

138. Lee TM, Ling CC. Preliminary observations on the treatment of Chinese kala-azar with pentamidine isothionate. Chin Med J (Peking, 1932–1966). 1951; 69:160-70.

139. Wittner M, Rowin KS, Tanowitz HB et al. Successful chemotherapy of transfusion babesiosis. Ann Intern Med. 1982; 96:601-4. [IDIS 150109] [PubMed 7200341]

140. Anon. Clindamycin and quinine treatment for Babesia microti infection. MMWR Morb Mortal Wkly Rep. 1983; 32:65-6,72. [PubMed 6405180]

141. Wien R, Freeman W, Scotcher NM. The metabolic effects produced by certain aromatic diamidines. Ann Trop Med Parasitol. 1943; 37:19-33.

142. Goble FC, Hoppe JO. Observations on the toxicity of certain trypanocidal quinaldines and aromatic diamidines. Antibiot Chemother (Washington, DC). 1952; 2:581-9.

143. Juranek DD (Centers for Disease Control, Atlanta, GA): Personal communication; 1985 Apr.

144. Fulton JD. The course of Plasmodium relictum infection in canaries and the treatment of bird and monkey malaria with synthetic bases. Ann Trop Med Parasitol. 1940; 34:53-66.

145. Jonchère H. Traitement par les diamidines de la phase lymphatico-sanguine de la trypanosomiase humaine en A.O.F. Bull Soc Pathol Exot Ses Fil. 1951; 44:603-25.

146. Gilbert FW. Preliminary report on pentamidine in the treatment of late cases of sleeping sickness. Trans R Soc Trop Med Hyg. 1943; 36:353-8.

147. Harding RD, Hutchinson MP. Mass prophylaxis against sleeping sickness in Sierra Leone: final report. Trans R Soc Trop Med Hyg. 1950; 43:503-12.

148. Jonchère H. Chimioprophylaxie de la trypanosomiase humaine en A.O.F. Bull Soc Pathol Exot Ses Fil. 1951; 44:83-93.

149. Gelfand M, Alves WD. Three early cases of Rhodesian sleeping sickness treated with pentamidine isethionate. Trans R Soc Trop Med Hyg. 1954; 48:146-9. [PubMed 13157160]

150. de Andrade Silva MA. The value of drugs commonly used in the treatment of T. rhodesiense sleeping sickness. An Inst Med Trop Lisbon. 1957; 14:159-70. [PubMed 13521347]

151. de Andrade Silva MA, Caseiro A. Prophylactic action of diamidines against T. rhodesiense infection. An Inst Med Trop Lisbon. 1957; 14:171-7. [PubMed 13521348]

152. Fendall NRE. Kala-azar in East Africa with particular reference to Kenya and the Kamba country. Part IV. Clinical studies. J Trop Med Hyg. 1952; 50:245-56.

153. Prasad KM, Singh BP, Nevatia SK et al. Re-emergence of kala-azar and resistance to drugs. Arch Child Health. 1979; 21(2):29-35.

154. Correa A, da Rocha Brito G. Traitement de la leishmaniose muqueuse Sud-Américaine par la diamidinophenoxypentane. Bull Soc Pathol Exot Ses Fil. 1954; 47:513-7.

155. Silva YP. Lomidine no tratamento da leishmaniose tegumentar. Hospital (Rio de Janeiro). 1952; 42:165-8, 171-4.

156. Shelhamer JH, Ognibene FP, Macher AM et al. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia. Am Rev Respir Dis. 1984; 130:1161-5. [IDIS 194604] [PubMed 6334462]

157. Small CB, Harris CA, Friedland GH et al. The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med. 1985; 145:837-40. [IDIS 199178] [PubMed 3873229]

158. Stehr-Green JK, Helmick CG. Pentamidine and renal toxicity. N Engl J Med. 1985; 313:694-5. [IDIS 204306] [PubMed 4022063]

159. Helmick CG, Green JK. Pentamidine-associated hypotension and route of administration. Ann Intern Med. 1985; 103:480. [IDIS 205833] [PubMed 4026103]

160. Specia. Lomidine (pentamidine mesylate) prescribing information. (French.) Paris, France; 1972.

161. Bryceson ADM (Hospital for Tropical Diseases, London): Personal communication; 1985 Jun.

162. De NC, Alam AS, Kapoor JN. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm. 1986; 43:1486-8. [PubMed 3728484]

163. Sensakovic JW, Saurez M, Perez G et al. Pentamidine treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: association with acute renal failure and myoglobinuria. Arch Intern Med. 1985; 145:2247. [IDIS 208401] [PubMed 3878136]

164. Shuster M, Dunn M. Pentamidine and hematuria. Ann Intern Med. 1986; 105:146. [IDIS 217867] [PubMed 3487266]

165. Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with acquired immune deficiency syndrome. Clin Pharmacol Ther. 1986; 39:271-5. [IDIS 213984] [PubMed 3485027]

166. Salmeron S, Petitpretz P, Katlama C et al. Pentamidine and pancreatitis. Ann Intern Med. 1986; 105:140-1. [IDIS 217861] [PubMed 3487265]

167. Wharton JM, Coleman DL, Wofsy CB et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective randomized trial. Ann Intern Med. 1986; 105:37-44. [IDIS 217841] [PubMed 3521428]

168. Zuger A, Wolf BZ, El-Sadr W et al. Pentamidine-associated fatal acute pancreatitis. JAMA. 1986; 256:2383-5. [IDIS 222552] [PubMed 3490588]

169. Andersen R, Boedicker M, Ma M et al. Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy. Drug Intell Clin Pharm. 1986; 20:862-8. [IDIS 222524] [PubMed 3490958]

170. Yurdakok M. Diabetogenic effect of pentamidine. JAMA. 1987; 257:1177. [PubMed 3543425]

171. Conte JE Jr, Upton RA, Phelps RT et al. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis. 1986; 154:923-9. [IDIS 224946] [PubMed 3491164]

172. Navin TR, Dickinson CM, Adams SR et al. Effect of azotemia in dogs on the pharmacokinetics of pentamidine. J Infect Dis. 1987; 155:1020-6. [PubMed 3559276]

173. Girard PM, Brun-Pascaud M, Farinotti R et al. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1987; 31:978-81. [PubMed 3499116]

174. Conte JE Jr, Hollander H, Golden JA. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia: a pilot study. Ann Intern Med. 1987; 107:495-8. [IDIS 234487] [PubMed 3498418]

175. Wharton JM, Demopoulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med. 1987; 83:571-6. [IDIS 234172] [PubMed 3499072]

176. Montgomery AB, Debs RJ, Luce JM et al. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet. 1987; 2:480-3. [IDIS 233332] [PubMed 2887779]

177. Jesuthasan AJ, Datta AK, Hamilton R et al. Aerosolised pentamidine. Lancet. 1987; 2:971-2. [IDIS 234824] [PubMed 2889891]

178. Heley A. Aerosolised pentamidine treatment at home. Lancet. 1987; 2:1092. [IDIS 235722] [PubMed 2890004]

179. Paton WDM. Aerosolised pentamidine. Lancet. 1987; 2:1146.

180. Sattler FR, Waskin H. Pentamidine and fatal hypoglycemia. Ann Intern Med. 1987; 107:789-90. [IDIS 235766] [PubMed 3662308]

181. Montgomery AB, Debs RJ, Luce JM et al. Selective delivery of pentamidine to the lung by aerosol. Am Rev Respir Dis. 1988; 137:477-8. [IDIS 314487] [PubMed 3257663]

182. Conte JE Jr, Golden JA. Concentrations of aeosolized pentamidine in bronchoalveolar lavage, systemic absorption, and excretion. Antimicrob Agents Chemother. 1988; 32:1490-3. [IDIS 246899] [PubMed 3263832]

183. Donnelly H, Bernard EM, Rothkotter H et al. Distribution of pentamidine in patients with AIDS. J Infect Dis. 1988; 157:985-9. [IDIS 242791] [PubMed 3258901]

184. Dusci LJ, Hackett LP, Forbes AM et al. High-performance liquid chromatographic method for measurement of pentamidine in plasma and its application in an immunosuppressed patient with renal dysfunction. Ther Drug Monit. 1987; 9:422-5. [IDIS 243012] [PubMed 3501181]

185. Conte JE Jr, Upton RA, Lin ET. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis. 1987; 156:885-90. [IDIS 243322] [PubMed 3680992]

186. Anon. Treatment of Pneumocystis carinii pneumonia. Med Lett Drugs Ther. 1987; 29:103-4. [PubMed 2959845]

187. Kovacs JA, Masur H. Pneumocystis carinii pneumonia: therapy and prophylaxis. J Infect Dis. 1988; 158:254-9. [IDIS 244493] [PubMed 2969023]

188. Sattler FR, Cowan R, Nielsen DM et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med. 1988; 109:280-7. [IDIS 244954] [PubMed 3260759]

189. Debs RJ, Blumenfeld W, Brunette EN et al. Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother. 1987; 31:37-41. [PubMed 3494424]

190. Godfrey-Faussett P, Miller RF, Semple SJ. Nebulised pentamidine. Lancet. 1988; 1:645-6. [IDIS 240201] [PubMed 2894573]

191. Girard PM, Couderc LJ, Farinotti R et al. Ultrasonic nebulised pentamidine for pneumocystis pneumonia. Lancet. 1988; 1:1165. [IDIS 242006] [PubMed 2896982]

192. Havlichek D. Aerosolized pentamidine therapy. Ann Intern Med. 1988; 109:167-8. [IDIS 244167] [PubMed 3260086]

193. Corkery KJ, Luce JM, Montgomery AB. Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia: an update. Respir Care. 1988; 33:676-85.

194. Raviglione MC, Garner GR, Mullen MP. Pneumocystis carinii in bone marrow. Ann Intern Med. 1988; 109:253. [PubMed 3260460]

195. Armstrong D, Bernard E. Aerosol pentamidine. Ann Intern Med. 1988; 109:852-4. [IDIS 248223] [PubMed 3056163]

196. Karaffa C, Rehm S, Calabrese L. Efficacy of monthly pentamidine infusions in preventing recurrent Pneumocystis carinii pneumonia (PCP) in the AIDS patient. Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA: American Society for Microbiology; 1986:690. Abstract.

197. Johnson ES, Sulieman S, Perez G et al. Secondary prophylaxis of PCP in AIDS patients using bimonthly parenteral pentamidine. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, NY: American Society for Microbiology; 1987:943. Abstract.

198. Merz B. Aerosolized pentamidine promising in Pneumocystis therapy, prophylaxis. JAMA. 1988; 259:3223-4. [PubMed 3259636]

199. Fishman JA. Treatment of infection due to Pneumocystis carinii Antimicrob Agents Chemother. 1998; 42:1309-14.

200. Abd AG, Nierman DM, Ilowite JS et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest. 1988; 94:329-31. [IDIS 244715] [PubMed 3260848]

201. Pujol M, Carratala J, Mauri J et al. Ventricular tachycardia due to pentamidine isethionate. Am J Med. 1988; 84:980. [IDIS 241210] [PubMed 3364459]

202. Waskin H, Stehr-Green JK, Helmick CG et al. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. JAMA. 1988; 260:345-7. [IDIS 243308] [PubMed 3259989]

203. Karboski JA, Godley PJ. Inhaled pentamidine and hypoglycemia. Ann Intern Med. 1988; 108:490. [IDIS 239636] [PubMed 3341691]

204. Lindley DA, Schleupner CJ. Aerosolized pentamidine and conjunctivitis. Ann Intern Med. 1988; 109:988. [IDIS 248617] [PubMed 3195880]

205. Conover B, Goldsmith JC, Buehler BA et al. Aerosolized pentamidine and pregnancy. Ann Intern Med. 1988; 109:927. [IDIS 248226] [PubMed 3190049]

206. Arnott MA, Hay J, Croft SL. Pentamidine: which salt? Lancet. 1988; 1:1057-8. Letter.

207. Bryceson A. Pentamidine: which salt? Lancet. 1988; 1:1395. Letter.

208. Smith DE, Herd D, Gazzard BG. Reversible bronchoconstriction with nebulised pentamidine. Lancet. 1988; 2:905. [IDIS 247039] [PubMed 2902344]

209. Alston TA. Inhibition of cholinesterases by pentamidine. Lancet. 1988; 2:1423. [IDIS 249117] [PubMed 2904548]

210. Greenberger PA, Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol. 1987; 79:484-8. [IDIS 227033] [PubMed 3819229]

211. Respiratory Care Service, San Francisco General Hospital. Guidelines for aerosolization of pentamidine. San Francisco; 1988 Oct.

212. Respiratory Care Service, San Francisco General Hospital. Guidelines for aerosolization of pentamidine for PCP prophylaxis. San Francisco; 1988 Oct.

213. Fisons Corporation. Pneumopent (pentamidine isethionate for inhalation). Prescribing information draft. Bedford, MA; 1988 May.

214. May and Baker Pharmaceuticals, Rhone-Poulenc Ltd. Pentacarinat (pentamidine isethionate sterile powder). Data sheet. Dagenham, Essex, England; 1988 Sep.

215. Martinez CM, Romanelli A, Mullen MP et al. Spontaneous pneumothoraces in AIDS patients receiving aerosolized pentamidine. Chest. 1988; 94:1317-8. [IDIS 310754] [PubMed 3263913]

216. LyphoMed, Inc. A treatment IND for the use of aerosolized pentamidine in HIV-infected individuals at high risk for Pneumocystis carinii pneumonia. Rosemont, IL (undated).

217. LyphoMed, Inc. Clinical investigator's brochure for aerosolized pentamidine treatment IND #32,642. Rosemont, IL; 1989 Jan 31.

218. LyphoMed, Inc. Instructions for the aerosolization of pentamidine for PCP prophylaxis. Rosemont, IL (undated).

219. American Pharmaceutical Partners. NubuPent (pentamidine isethionate) for oral inhalation prescribing information. Los Angeles, CA; 1999 Mar.

220. Anon. Pentamidine aerosol to prevent Pneumocystis carinii pneumonia. Med Lett Drugs Ther. 1989; 31:91-2. [PubMed 2571064]

221. Kovacs JA, Masur H. Prophylaxis of Pneumocystis carinii pneumonia: an update. J Infect Dis. 1989; 160:882-6. [IDIS 307861] [PubMed 2681438]

222. Girard PM, Landman R, Gaudebout C et al. Prevention of pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients. Lancet. 1989; 1:1348-53. [IDIS 256674] [PubMed 2567372]

223. Luce JM, Hopewell PC. Aerosolized pentamidine for Pneumocystis carinii pneumonia. Chest. 1989; 96:713-4. [IDIS 305758] [PubMed 2791660]

224. Montgomery AB, Debs RJ, Luce JM et al. Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia. Chest. 1989; 95:747-50. [IDIS 305623] [PubMed 2784371]

225. Miller RF, Godfrey-Faussett P, Semple SJG. Nebulized pentamidine as treatment for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Thorax. 1989; 44:565-9. [PubMed 2788936]

226. Goto H, Oka S, Mohri H et al. Two cases of Pneumocystis carinii pneumonia occurred in human immunodeficiency virus infected patients: supplemental treatment with aerosolized pentamidine isethionate. Jpn J Med. 1989; 28:105-9. [PubMed 2786100]

227. Armstrong D, Bernard E. Aerosolized pentamidine. Ann Intern Med. 1989; 110:574.

228. Montgomery AB, Feigal DW, Luce JM et al. Aerosolized pentamidine and Pneumocystis carinii pneumonia. Ann Intern Med. 1989; 110:669. [IDIS 253264] [PubMed 2648925]

229. Bellin E. Aerosolized pentamidine. Ann Intern Med. 1989; 110:408. [PubMed 2916812]

230. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1989; 38(Suppl 5):1-9.

231. LyphoMed, Inc. NebuPent (pentamidine isethionate) for inhalation solution product monograph (NebuPent-004). Rosemont, IL; 1989 Jun.

232. O'Doherty MJ, Thomas SHL, Nunan TO et al. Aerosolised pentamidine. Lancet. 1989; 1:501-2. [PubMed 2563874]

233. O'Doherty MJ, Thomas S, Page C et al. Differences in relative efficiency of nebulisers for pentamidine administration. Lancet. 1988; 2:1283-6. [IDIS 248376] [PubMed 2904008]

234. Anon. Choosing a nebulizer for pentamidine delivery. Am J Hosp Pharm. 1989; 46:1210.

235. Simonds AK, Newman SP, Johnson MA et al. Aerosolised pentamidine. Lancet. 1989; 1:221-2. [IDIS 250437] [PubMed 2563131]

236. Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med. 1989; 87:329-31. [IDIS 258426] [PubMed 2788999]

237. Leoung GS, Montgomery AB, Abrams DJ et al. Aerosol pentamidine for Pneumocystis carinii pneumonia prophylaxis: a 3 arm randomized trial. Fifth International Conference on AIDS. Montreal; 1989:196. Abstract T.B.0.3.

238. Montaner JSG, Lawson L, Falutz J et al. Aerosolized pentamidine for the secondary prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a report from the Canadian Cooperative Trial. Fifth International Conference on AIDS. Montreal; 1989:295. Abstract. No. T.B.P.54.

239. Sparling TG, Dong SR, Hegedus C et al. Aerosolized pentamidine and disseminated infection with Pneumocystis carinii. Ann Intern Med. 1989; 111:442. [IDIS 258650] [PubMed 2788380]

240. Hagopian WA, Huseby JS. Pneumocystis hepatitis and choroiditis despite successful aerosolized pentamidine pulmonary prophylaxis. Chest. 1989; 4:949-51.

241. Bradburne RM, Ettensohn DB, Opal SM et al. Relapse of Pneumocystis carinii pneumonia in the upper lobes during aerosol pentamidine prophylaxis. Thorax. 1989; 44:591-3. [PubMed 2788937]

242. Berger TG, Tappero JW, Leoung GS et al. Aerosolized pentamidine and cutaneous eruptions. Ann Intern Med. 1989; 110:1035-6. [IDIS 255913] [PubMed 2524983]

243. Lingenfelser T, Glück T, Scheurlen M et al. Pentamidine and hypoglycaemia. Lancet. 1989; 2:458. [IDIS 258090] [PubMed 2569646]

244. Miller RF, Delany S, Semple SJG. Acute renal failure after nebulised pentamidine. Lancet. 1989; 1:1271-2.

245. Miller RF, Semple SJG. Bronchial bleeding with nebulised pentamidine. Lancet. 1988; 2:1488.

246. Hart CC. Aerosolized pentamidine and pancreatitis. Ann Intern Med. 1989; 111:691. [IDIS 259891] [PubMed 2802428]

247. Young FE, Nightingale SL, Cooper EC et al. Aerosolized pentamidine: approved for HIV-infected individuals at high risk for Pneumocystis carinii pneumonia. Arch Intern Med. 1989; 149:2412-3. [IDIS 260608] [PubMed 2818104]

248. Pierone G, Turett G, Masci JR et al. Inhaled pentamidine in pneumocystis carinii pneumonia. Lancet. 1989; 2:559. [IDIS 258659] [PubMed 2570253]

249. Poblete RB, Rodriguez K, Foust RT et al. Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1989; 110:737-8. [IDIS 254416] [PubMed 2784649]

250. Anon. Mycobacterium tuberculosis transmission in a health clinic—Florida, 1988. MMWR Morb Mortal Wkly Rep. 1989; 38:256-7, 263-4. [PubMed 2495425]

251. Gude JK. Selective delivery of pentamidine to the lung by aerosol. Am Rev Respir Dis. 1989; 139:1060. [IDIS 252763] [PubMed 2784644]

252. McDiarmid MA, Jacobson-Kram D. Aerosolised pentamidine and public health. Lancet. 1989; 2:863-4. [IDIS 259598] [PubMed 2571783]

253. Masur H, Lane HC, Kovacs JA et al. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med. 1989; 111:813-26. [IDIS 261003] [PubMed 2683916]

254. Pierone G, Masci JR, Nicholas P. Pentamidine and hypoglycaemia. Lancet. 1989; 2:864. [IDIS 259599] [PubMed 2571784]

255. LyphoMed, Inc. Administering NebuPent (pentamidine isethionate) with the Respirgard II nebulizer system (product information). Rosemont, IL; 1989 Jun.

256. Blumenfeld W, Basgoz N, Owen WF Jr et al. Granulomatous pulmonary lesions in patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii infection. Ann Intern Med. 1988; 109:505-7. [PubMed 3261957]

257. Goldfarb J. Intravenous saline as adjunctive therapy for patients with AIDS given pentamidine. N Engl J Med. 1989; 320:1281. [IDIS 254312] [PubMed 2785244]

258. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989; 87:260-3. [IDIS 258417] [PubMed 2773964]

259. Peltz S, Hashmi S. Pentamidine-induced severe hyperkalemia. Am J Med. 1989; 87:698-9. [IDIS 261830] [PubMed 2589407]

260. Dalpra M. (LyphoMed, Inc., Chicago, IL); personal communication: 1990 Jan 2.

261. Montgomery AB, Corkery KJ, Brunette ER et al. Occupational exposure to aerosolized pentamidine. Chest. 1990; 98:386-8. [PubMed 2376170]

262. Doll DC. Aerosolised pentamidine. Lancet. 1989; 2:1284-5. [IDIS 261381] [PubMed 2573803]

263. Thomas SHL, Page CM, O'Doherty MJ et al. Aerosolised pentamidine. Lancet. 1989; 2:1284. [IDIS 261381] [PubMed 2573803]

264. Kacmarek RM. Ribavirin and pentamidine aerosols: caregiver beware! Respir Care. 1990; 35:1034-6.

265. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997; 24:684-703. [IDIS 384365] [PubMed 9145744]

266. Young FE, Norris JA, Levitt JA et al. The FDA's new procedures for the use of investigational drugs in treatment. JAMA. 1988; 260:224-5. [PubMed 2838651]

267. Nightingale SL. From the Food and Drug Administration. JAMA. 1988; 259:2064.

268. Anon. Treatment IND for AIDS drug. FDA Drug Bull. 1988; 18:2.

269. Allegra CJ, Chabner BA, Tuazon CU et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987; 317:978-85. [IDIS 234181] [PubMed 2958710]

270. AIDS Program, Treatment Branch, National Institute of Allergy and Infectious Diseases and Warner-Lambert Company. A treatment protocol for the use of trimetrexate with leucovorin rescue for AIDS patients with Pneumocystis carinii pneumonia and serious intolerance to approved therapies. No. TX 301. Bethesda, MD; 1988 Jun 7.

271. Buff DD, Aboal AA. Pentamidine-associated renal dysfunction and hyperkalemia. Am J Med. 1990; 88:552. [IDIS 266349] [PubMed 2337115]

272. Marino PL. Pentamidine and hyperkalemia revisited. Am J Med. 1990; 89:397. [IDIS 271039] [PubMed 2393048]

273. Peltz S, Hashmi S. Pentamidine and hyperkalemia revisited. Am J Med. 1990; 89:397-8. [IDIS 271039] [PubMed 2393048]

274. Murphy RL, Noskin FA, Ehrenpreis ED. Acute pancreatitis associated with aerosolized pentamidine. Am J Med. 1990; 88(Suppl 5):5-53-6N.

275. Fisch A, Prazuck T, Malkin JE et al. Diabetes mellitus in a patient with AIDS after treatment with pentamidine aerosol. Br Med J. 1990; 301:875.

276. Sneed SR, Blodi CF, Berger BB et al. Pneumocystis carinii choroiditis in patients receiving inhaled pentamidine. N Engl J Med. 1990; 322:936-7. [IDIS 264362] [PubMed 2314433]

277. Conte JE Jr, Chernoff D, Feigal DW Jr et al. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS: a randomized trial. Arch Intern Med. 1990; 113:203-9.

278. Leoung GS, Feigal DW Jr, Montgomery AB et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: the San Francisco community prophylaxis trial. N Engl J Med. 1990; 323:769-75. [IDIS 270539] [PubMed 1975426]

279. Soo Hoo GW, Mohsenifar Z, Meyer RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS: a randomized trial. Arch Intern Med. . 1990; 113:195-202.

280. Duma RJ, Finley R. In vitro susceptibility of pathogenic Naegleria and Acanthamoeba species to a variety of therapeutic agents. Antimicrob Agents Chemother. 1976; 10:370-6. [IDIS 66432] [PubMed 984777]

281. Jules-Elysee KM, Stover DM, Zaman MB et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med. 1990; 112:750-7. [IDIS 265985] [PubMed 2331119]

282. Raoult D, Soulayrol L, Toga B et al. Babesiosis, pentamidine, and cotrimoxazole. Ann Intern Med. 1987; 107:944. [IDIS 237481] [PubMed 3500663]

283. Benezra D, Brown AE, Polsky B et al. Babesiosis and infection with human immunodeficiency virus (HIV). Ann Intern Med. 1987; 107:944. [IDIS 237480] [PubMed 3688692]

284. Baskin MI, Abd AG, Ilowite JS. Regional disposition of aerosolized pentamidine: effects of body position and breathing pattern. Ann Intern Med. 1990; 113:677-83. [IDIS 273232] [PubMed 2221648]

285. Diagnostic and Therapeutic Technology Assessment (DATTA) panel. Prophylactic treatment for opportunistic infections in HIV-positive patients: aerosolized pentamidine. JAMA. 1990; 263:2510-4. [PubMed 2184263]

286. Stranberg RW. Guidelines to prevent employee exposure to aerosolized pentamidine. CAL/OSHA Information Bulletin. San Francisco, CA; 1990 Sep 9.

287. Center for Disease Control, Commonwealth of Massachusetts Department of Public Health. Guidelines to reduce the risk of airborne tuberculosis (TB) transmission. Boston, MA; 1989 Jun 15.

288. Wardlaw LA, Schecter GF, Kandal K et al. Risk of TB transmission in AIDS patients receiving aerosolized pentamidine treatment. Am Rev Respir Dis. 1990; 141(Part 2):A150.

289. Riley RL, Nardell EA. Clearing the air: the tehory and application of ultraviolet air disinfection. Am Rev Respir Dis. 1989; 139:1286-94. [PubMed 2653151]

290. Murphy RL, Lavelle JP, Allan JD et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose comparison study using an ultrasonic nebulizer. Am J Med. 1991; 90:418-26. [IDIS 280109] [PubMed 2012082]

291. Falloon J, Masur H. The era of pentamidine prophylaxis: the beginning of the end? Am J Med. 1991; 90:415-7. Editorial.

292. Montaner JSG, Lawson LM, Gervais A et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: a randomized, placebo-controlled study. Ann Intern Med. 1991; 114:948-53. [IDIS 281383] [PubMed 2024862]

293. Smaldone GC, Perry RJ, Deutsch DG. Characteristics of nebulizers used in the treatment of AIDS-related Pneumocystis carinii pneumonia. J Aerosol Med. 1988; 1:113-26.

294. Smaldone RC, Vinciguerra C, Marchese J. Detection of inhaled pentamidine in health care workers. N Engl J Med. 1991; 325:891-2. [IDIS 285443] [PubMed 1875979]

295. Hirschel B, Lazzarin A, Chopard P et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med. 1991; 324:1079-83. [IDIS 279604] [PubMed 2008181]

296. Smaldone GC, Fuhrer J, Steigbigel RT et al. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1991; 143:727-37. [IDIS 280712] [PubMed 2008984]

297. Doepel LK. HHS news regarding an inexpensive drug (co-trimoxazole) used to treat Pneumocystis carinii pneumonia (PCP) has been found to be superior to the only drug (pentamidine) currently approved for PCP prophylaxis in preventing a second episode of PCP. US Department of Health and Human Sevices Public Health Service. 1991 Sep 6.

298. National Institute of Allergy and Infectious Diseases backgrounder: questions and answers about ACTG protocol 021 and PCP prevention. Bethesda, MD: National Institutes of Health Office of Communications; 1991 Sep 6.

299. Working Group on PCP prophylaxis in children. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1991; 40(Suppl RR-2):1-13. [PubMed 1898620]

300. Anon. Guidelines established for PCP prophylaxis in infants and children infected with HIV. NIAID AIDS Agenda. 1991; (Mar/Apr):6.

301. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA. 1991; 266:820-824. [IDIS 284254] [PubMed 1907671]

302. Connor E, Bagarazzi M, McSherry G et al. Clinical and laboratory correlates on Pneumocystis carinii pneumonia in children infected with HIV. JAMA. 1991; 265:1693-7. [IDIS 279599] [PubMed 1672168]

303. Committee on Infectious Diseases, American Academy of Pediatrics. 2000 Red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 365-7,460-5,590-1.

304. Kovacs A, Frederick T, Church J et al. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. JAMA. 1991; 265:1698-1703. [PubMed 1672169]

305. Ruskin J, LaRiviere M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet. 1991; 337:468-71. [IDIS 278303] [PubMed 1671479]

306. Freedberg KA, Tosteson ANA, Cohen CJ et al. Inhaled pentamidine and prevention of pneumocystis pneumonia. N Engl J Med. 1991; 325:735. [IDIS 284642] [PubMed 1908059]

307. Bender BS. Inhaled pentamidine and prevention of pneumocystis pneumonia. N Engl J Med. 1991; 325:736.

308. National Institute of Allergy and Infectious Diseases Division of AIDS. Note to physicians: important therapeutic information on prevention of recurrent Pneumocystis carinii pneumonia in persons with AIDS. Bethesda, MD: National Institutes of Health; 1991 Oct 11.

309. Allen UD, Read SE. Pneumocystis carinii pneumonia [PCP] prophylaxis for HIV-infected infants: a decision analysis. Program and abstracts of the thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society for Microbiology; 1991 Sep 29-Oct 2. Abstract No. 627.

310. US Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients With Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1992; 41(No. RR-4):1-11.

311. Anon. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV. JAMA. 1992; 267:2294-9. [PubMed 1348788]

312. Kovacs JA, Masur H. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992; 14:1005-9. [IDIS 295394] [PubMed 1350925]

313. Carr A, Tindall B, Brew BJ et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992; 117:106-11. [IDIS 299034] [PubMed 1351371]

314. Beaman MH, Luft BJ, Remington JS. Prophylaxis for toxoplasmosis in AIDS. Ann Intern Med. 1992; 117:1163-4.

315. Quieffin J, Hunter J, Schecter MT et al. Aerosol pentamidine-induced bronchoconstriction: predictive factors and preventive therapy. Chest. 1991; 100:624-7. [IDIS 288845] [PubMed 1832372]

316. Leigh TR, Wiggins J, Gazzard B et al. A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionate. Respir Med. 1991; 85:527-31. [PubMed 1663642]

317. Winslow D, Bincsik A, Lincoln P et al. Secondary prophylaxis of Pneumocystis carinii pneumonia with systemic pentamidine. Int Conf AIDS. 1989; 5:294.

318. Levine SJ, Masur H, Gill VJ et al. Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. Ann Rev Respir Dis. 1991; 144:760-4.

319. US Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1993; 6:46-55. [PubMed 8417174]

320. Weverling GJ, Mocroft A, Legergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA study group. Lancet. 1999; 531:1293-8.

321. Cheung TW, Matta R, Neibart E et al. Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clin Infect Dis. 1993; 16:22-5. [IDIS 307822] [PubMed 8448314]

322. Underwood TW, Frye CB. Drug-induced pancreatitis. Clin Pharm. 1993; 12:440-8. [IDIS 314327] [PubMed 8403815]

323. Nybo Jensen B, Lynghoj Nielsen T, Backer V et al. Aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a controlled, randomized trial. J Acquir Immune Defic Syndr. 1993; 6:472-7. [PubMed 8097788]

324. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM et al. A controlled trial of aerosolized pentamidine or trimethoprim–sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med. 1992; 327: 1836-41.

325. Hardy WD, Feinberg J, Finkelstein DM et al. A controlled trial of trimethoprim–sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patient with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. N Engl J Med. 1992; 327:1842-8. [IDIS 306717] [PubMed 1448121]

326. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med. 1992; 327:1853-60. [IDIS 306718] [PubMed 1448123]

327. National Institutes for Allergy and Infectious Disease, Bethesda, MD: Personal communication.

328. Marinas JS, Stanford JF. A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus. Clin Infect Dis. 1993; 16:178-9. [IDIS 307837] [PubMed 8448304]

329. Abbott Laboratories. Sterile pentamidine isethionate fliptop vial prescribing information. Abbott Park, IL; 1992 Apr.

330. Harb GE, Jacobson MA. Human immunodeficiency virus (HIV) infection: does it increase susceptibility to adverse drug reactions? Drug Safety. 1993; 9:1-8.

331. Martin GJ, Paparello SF, Decker CF. A severe systemic reaction to trimethoprim-sulfamethoxazole in a patient infected with the human immunodeficiency virus. Clin Infect Dis. 1993; 16:175-6. [IDIS 307836] [PubMed 8448303]

332. Coopman SA, Johnson RA, Platt R et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993; 328:1670-4. [IDIS 315175] [PubMed 8487826]

333. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis. 1992; 14:773-9. [IDIS 292453] [PubMed 1314104]

334. Kelly JW, Dooley DP, Lattuada CP et al. A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992; 14:1034-9. [IDIS 295397] [PubMed 1600003]

335. O'Neil MG, Selub SE, Hak LJ. Pancreatitis during pentamidine therapy in patients with AIDS. Clin Pharm. 1991; 10:56-9. [IDIS 276570] [PubMed 1999087]

336. Pretet S, Salmon D, Rousseau F et al. Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. Am J Med. 1993; 94:35-40. [IDIS 308519] [PubMed 8420298]

337. Jones RS Jr, Collier-Brown C, Suh B. Localized cutaneous reaction to intravenous pentamidine. Clin Infect Dis. 1992; 15:561-2. [IDIS 301082] [PubMed 1387809]

338. McDiarmid MA, Fujikawa J, Schaefer J et al. Health effects and exposure assessment of aerosolized pentamidine handlers. Chest. 1993; 104:382-85. [IDIS 319800] [PubMed 8339622]

339. Golden JA, Katz MH, Chernoff DN et al. A randomized comparison of once-monthly or twice-monthly high-dose aerosolized pentamidine prophylaxis. Chest. 1993; 104:743-50. [IDIS 319956] [PubMed 8365284]

340. Dupon M, Malou M, Rogues AM et al. Acute eosinophilic pneumonia induced by inhaled pentamidine isethionate. BMJ. 1993; 306:109. [IDIS 308076] [PubMed 8435603]

341. U.S. Bioscience, Inc. Neutrexin (trimetrexate glucuronate) for injection prescribing information. In: Barnhart ER, publisher. Physicians' desk reference. 48th ed. Oradell, NJ: Medical Economic Company Inc; 1994(Suppl A):A44-7.

342. May T, Beuscart C, Reynes J et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. J Acquir Immune Defic Syndr. 1994; 7:457-62. [IDIS 328947] [PubMed 8158539]

343. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994; 120:932-44. [IDIS 330617] [PubMed 8172439]

344. Smith GH. Treatment of infections in the patient with acquired immunodeficiency syndrome. Arch Intern Med. 1994; 154:959-73.

345. Osmond D, Charlebois E, Lang W et al. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA. 1994; 271:1083-7. [PubMed 7908703]

346. Rigaud M. Pollack H, Leibovitz E et al. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr. 1994; 125:476-80. [IDIS 335631] [PubMed 7915306]

347. National Institutes of Health Combined Clinical Staff Conference. Consensus conference: recent advances in the mangaement of AIDS-related opportunistic infections. Ann Intern Med. 1994; 120:945-55. [IDIS 330618] [PubMed 7909657]

348. Kovacs JA, Kovacs AAS. PCP prophylaxis in paediatric HIV infection: time for a change? Lancet. 1994; 344:5-6. Letter.

349. Hoover DR, Saah AJ, Bacellar H et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med. 1993; 329:1922-6. [PubMed 7902536]

350. Weiss PJ, Wallace MR. Aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia: what is the correct dose? Clin Infect Dis. 1994; 18:257-8. Letter.

351. Hand IL, Wiznia AA, Porricolo M et al. Aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in infants with human immunodeficiency virus infection. Pediatr Infect Dis J. 1994:13(2):100-4.

352. Zanetti LAF. Pentamidine-induced torsades de pointes. Ann Pharmacother. 1994; 28:282-3.

353. Ena J, Amador C, Pasquau F et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis. 1994; 18:901-4. [IDIS 331745] [PubMed 8086550]

354. Dohn MN, Weinberg WG, Torres RA et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1994; 121:174-80. [IDIS 332897] [PubMed 7880228]

355. Schwebke K, Fletcher CV, Acost EP et al. Pentamidine concentrations in a mother with AIDS and in her neonate. Clin Infect Dis. 1995; 20:1569-70. [IDIS 349029] [PubMed 7548518]

356. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.

357. Furrer H, Egger M, Opravil M et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med. 1999; 340:1301-6. [IDIS 425566] [PubMed 10219064]

358. Centers for Disease Control and Prevention. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1995; 44(No. RR-4):1-11. [PubMed 7799912]

359. Schneider MME, Borleffs JCC, Stolk RP et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet. 1999; 353:201-3. [IDIS 418064] [PubMed 9923876]

360. Dworkin MS, Hanson DL, Kaplan JE et al. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. 2000; 182:611-5. [PubMed 10915098]

361. Mussini C, Pezzotto P, Govoni A et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficient virus type 1-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis. 2000; 181:1635-42. [IDIS 447385] [PubMed 10823763]

362. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection: Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001; 344:159-67. [IDIS 458267] [PubMed 11172138]

363. Furrer H, Opravil M, Rossi M et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS. 2001; 15:501-7. [PubMed 11242147]

364. Kirk O, Lundgren JD, Pedersen C et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS. 1999; 13:1647-51.

365. Soriano V, Dona C, Rodriguez-Rosado R et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2000; 14:383-6. [PubMed 10770540]

366. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med. 2001; 344:168-74. [IDIS 458268] [PubMed 11188837]

HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1314-6.

b. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs. 1998; 56:1009-18. [PubMed 9878989]

Hide
(web2)